Orion Biotechnology: Unlocking the Therapeutic Potential of Complex GPCRs Using a Novel Modality

Time: 12:30 pm
day: Day Two


  • Unlocking the therapeutic potential of GPCRs with a novel drug modality and purpose-built discovery platform
  • Addresses previously undruggable GPCR targets by precision engineering ligands of peptide and protein GPCRs to develop analogs with superior binding affinity, potency, and pharmacological control, offering significant advantages over small molecule and antibody approaches
  • Advancing a diversified pipeline of potential first-in-class/best-in-class therapeutics against high value GPCR targets in oncology and other serious diseases